<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998396</url>
  </required_header>
  <id_info>
    <org_study_id>CVN-102</org_study_id>
    <nct_id>NCT04998396</nct_id>
  </id_info>
  <brief_title>A Study of AAV9 Gene Therapy in Participants With Canavan Disease</brief_title>
  <acronym>CANaspire</acronym>
  <official_title>A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspa Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic&#xD;
      activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants&#xD;
      with Canavan disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Canavan disease is an ultra-rare, profoundly disabling and fatal disease with no approved&#xD;
      therapy. The Sponsor is developing BBP-812, an investigational gene therapy product for&#xD;
      systemic delivery in participants with Canavan disease. BBP-812 is a recombinant&#xD;
      adeno-associated virus serotype 9 (rAAV9) vector engineered to deliver the aspartoacylase&#xD;
      (ASPA) transgene under control of a ubiquitous promoter to restore ASPA expression in both&#xD;
      neuronal and non-neuronal cell types.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to 12 Months Post-Infusion in Urine N-acetylaspartate (NAA) Levels</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to 12 Months Post-Infusion in Central Nervous System (CNS) NAA, as Measured by Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in Gross Motor Assessment, Gross Motor Function Measure-88</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in Fine Motor Assessment, Bayley-4</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in Cognitive Assessment, Bayley-4</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in Communication Assessment, Bayley-4</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in Adaptive Function, Vineland-3</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Canavan Disease</condition>
  <condition>Demyelinating Diseases</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <condition>Metabolic Disease</condition>
  <condition>Neurological Diseases or Conditions</condition>
  <condition>Leukodystrophy</condition>
  <condition>Leukoencephalopathies</condition>
  <condition>Neurodevelopmental Disorders</condition>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enrollment Expansion Phase: BBP-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of BBP-812 at a selected dose from the dose-finding phase on Day 0 in expansion phase of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV9 BBP-812</intervention_name>
    <description>Sterile solution for injection for 1-time use via volumetric infusion pump</description>
    <arm_group_label>Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)</arm_group_label>
    <arm_group_label>Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)</arm_group_label>
    <arm_group_label>Enrollment Expansion Phase: BBP-812</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Maximum age for inclusion is 30 months.&#xD;
&#xD;
          -  Participant has stable health in the opinion of the investigator and as confirmed by&#xD;
             medical history and laboratory studies with no acute or chronic hematologic, renal,&#xD;
             liver, immunologic, or neurologic disease (other than Canavan disease).&#xD;
&#xD;
          -  Participant has biochemical, genetic, and clinical diagnosis of Canavan disease:&#xD;
&#xD;
               -  Elevated urinary NAA and&#xD;
&#xD;
               -  Biallelic mutation of the ASPA gene determined at Screening or documented in the&#xD;
                  participant's medical history.&#xD;
&#xD;
               -  Active clinical signs of Canavan disease&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Tests positive for total anti-AAV9 antibodies determined by enzyme-linked&#xD;
             immunosorbent assay (ELISA).&#xD;
&#xD;
          -  Received prior gene therapy or other therapy (including vaccines) involving AAV.&#xD;
&#xD;
          -  Participant is receiving high-dose therapy with immunosuppressants.&#xD;
&#xD;
          -  Participant has significantly progressed Canavan disease characterized as:&#xD;
&#xD;
               -  Presence of continuous/constant decerebrate or decorticate posturing,&#xD;
&#xD;
               -  Recurrent status epilepticus, or&#xD;
&#xD;
               -  Recalcitrant seizures that do not respond while on 3 or more anti-epileptic&#xD;
                  medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Canavan Disease Study Team</last_name>
    <phone>833-764-2267 or 617-861-4617</phone>
    <email>CANaspire@aspatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen M Kirby</last_name>
    <phone>978-479-7640</phone>
    <email>clinicaltrials@aspatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Andonian</last_name>
      <email>handonian@partners.org</email>
    </contact>
    <contact_backup>
      <phone>617-724-1379</phone>
    </contact_backup>
    <investigator>
      <last_name>Florian Eichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aspatx.com</url>
    <description>Aspa Therapeutics Company Website</description>
  </link>
  <link>
    <url>http://treatcanavan.com</url>
    <description>Canavan Disease Program Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canavan Disease</keyword>
  <keyword>AAV</keyword>
  <keyword>AAV9</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Aspartoacylase</keyword>
  <keyword>ASPA</keyword>
  <keyword>ASPA gene</keyword>
  <keyword>rAAV9</keyword>
  <keyword>ACY2</keyword>
  <keyword>Aminoacylase 2</keyword>
  <keyword>Spongy degeneration</keyword>
  <keyword>N-acetyl-L-aspartic acid (NAA)</keyword>
  <keyword>N-acetylaspartate</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Inherited Metabolic Disorders</keyword>
  <keyword>Leukodystrophy</keyword>
  <keyword>Leukoencephalopathies</keyword>
  <keyword>Autosomal Recessive Disorder</keyword>
  <keyword>Neurodevelopmental diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Canavan Disease</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Neurodevelopmental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

